Why is blood pressure awareness so important? In this video, Prof. Neil Poulter explains how May Measurement Month (MMM) and the #BecauseISaySo campaign work together to encourage people to measure their blood pressure. High blood pressure is the leading contributor to death worldwide, yet many people remain unaware they have it. Raising awareness and promoting regular blood pressure checks are essential steps to ensure hypertension is diagnosed and treated. Learn more 👉 #AsOne #BecauseISaySo #HypertensionAwareness #BloodPressure #MMM #CardiovascularHealth
À propos
Fondé il y a 70 ans pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance garantit son indépendance et lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardio-métabolisme et en maladies veineuses, Servier a opéré un virage majeur en oncologie qui constitue un nouveau pilier de croissance stratégique. Le Groupe y consacre près de 70 % de son budget de R&D, avec l’ambition de devenir un acteur focalisé et innovant dans le développement de traitements ciblant les cancers rares. La neurologie constitue un futur relais de croissance. Dans ce domaine, Servier se focalise sur un nombre restreint de pathologies dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est et au Brésil. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur des équipes engagées et une solide implantation géographique, avec des médicaments disponibles dans près de 140 pays. Le Groupe a réalisé un chiffre d’affaires de 5,9 Mds € en 2023/2024 et 1,3 Md € d’EBITDA (22,2 %) en 2024. Il compte aujourd’hui plus de 22 000 collaborateurs dans le monde. -- Pour signaler un évènement indésirable suspecté d’être lié à un médicament Servier, veuillez consulter
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
Obtenir l’itinéraire
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
Today is World Hypertension Day! As the world’s 1st leading pharmaceutical group in hypertension, we are committed to working alongside patients and health care professionals 👩⚕️🧑⚕️. 💬❤️ Through the #BecauseISaySo campaign, at Servier, we reaffirm our commitment to raising awareness and improving blood pressure control by giving a voice to patients and caregivers. This initiative reflects our conviction that listening to patients is essential to better prevention, earlier diagnosis and improved long-term outcomes. 🌍 👉 Discover the campaign and why blood pressure control matters: https://lnkd.in/eYhDui5T Together, let’s turn awareness into action. 💪🌍 #WeAreServier #MovedByYou #WorldHypertensionDay #CheckYourBloodPressure
-
You can’t control everything in life: traffic jams, work stress, family ups and downs… But your blood pressure? That’s something you can control. 💙 Join us to make sure 🔥🚀 everyone you love gets their blood pressure checked! 🗣️ Spread the word and share our Facebook and Instagram campaigns? 🚨 Why does it matter? High blood pressure is a silent condition and one of the leading causes of premature death. It is often associated with cardiometabolic and vascular risks. ⏰ The time to act is now. #CheckYourBloodPressure — because we say so. ❤️ By checking your blood pressure regularly, you take an important step to protect your health, prevent strokes and heart attacks, and live with greater peace of mind. 👉 Learn more about hypertension: https://bit.ly/3E7s4Lj #BecauseISaySo #TakeControl #HypertensionAwareness #HeartHealth #BloodPressure
-
🤝 Strengthening our culture means strengthening our ability to move forward together, and this year showed how powerful that collective momentum can be. 🎓 In 2024/2025, our teams embraced a major cultural evolution through Culture Up, a Group‑wide experience designed to reinforce collaboration, accountability, and innovation in our daily ways of working. With a 93% employee adherence, and 97% of participants ready to adopt new reflexes, this initiative marks an important step in shaping our shared future. This transformation was built on an in‑depth diagnostic conducted with 3,600 managers and all employees, leading to four cultural traits that now guide how we work and lead together. Developing people and leadership remains a core priority. Through the Servier Leadership Model (SLM) and our Servier &U Academy, awarded a silver medal at the 2024 Brandon Hall Awards, we continue to support learning, growth, and leadership excellence across the Group. Discover our annual report at 👉 https://lnkd.in/eKtYVYaA #WeAreServier #MovedByYou #CultureUp
-
The #HeartFailure26 congress is now over! We were delighted to take part in this key congress and to share our commitment to innovation in cardiology — always guided by patients’ needs.🫀 Engaging discussions, scientific exchanges, and a shared commitment to improving the lives of patients with heart failure made this event truly meaningful. Learn more about our long‑term commitment to cardiology 🔗 https://lnkd.in/eer4QWGZ Thank you to all partners, experts, and colleagues who made this congress a success. See you at the next scientific milestone! 🌍🔬 #WeAreServier #MovedByYou #HeartFailure European Society of Cardiology
-
-
🌍 Driving positive impact for people, communities, and the planet is a fundamental part of our mission. ⚡ This year, 10 of our industrial and R&D sites were powered 100% by renewable electricity, reflecting our commitment to reducing our environmental footprint. 💙 Through the Mécénat Servier Charity Fund, we provided financial support to 20 non‑profit organizations across 24 countries, helping extend positive impact to the communities where we operate. Discover our annual report at 👉 https://lnkd.in/eKtYVYaA #AnnualReport #MovedByYou #Sustainability
-
💪 A workplace where people feel valued, supported, and empowered, that’s what truly makes a difference for us. 86% of employees recommend Servier as a great place to work, a remarkable sign of trust and pride shared across our teams. 📈 Our employee’s engagement continues to rise, reflected in an overall engagement score of 4.35/5 in 2025 (vs. 4.33/5 last year), showing a collective commitment to our mission and to one another. 👩💼 And with 50% of managers in the Group being women, we are reinforcing a leadership culture built on diversity, inclusion, and equal opportunity. Discover our annual report at 👉 https://lnkd.in/eKtYVYaA #AnnualReport #MovedByYou #EmployerBrand
-
We’ll attending the #HeartFailure26 congress, one of the leading international events dedicated to advancing care for patients with heart failure. This congress is a key opportunity to connect with the global cardiovascular community, share scientific insights, and reaffirm our commitment to innovation in cardiology — always guided by patients’ needs. 🤝 Meet us at our booth – N° A100 and join our symposium: 🗓 May 10 | 2:30–3:15 pm (CEST) 🔬 “Polymedication in heart failure: time to simplify the regimen?” Learn more about our long‑term commitment in cardiology 🔗 https://lnkd.in/eer4QWGZ We look forward to connecting with you in person and exchanging on the future of cardiovascular care 🚀 #WeAreServier #MovedByYou #HeartFailure European Society of Cardiology
-
📣 There are things in life you just can’t control: traffic, deadlines, the weather… But your blood pressure? That’s something you can control. #CheckYourBloodPressure 🚨 High blood pressure is a silent disease and one of the leading causes of premature death. It is often linked to other risks such as cardiometabolic and venous diseases. Committed to helping patients, we are back 🚀🔥 with a new season of our #BecauseIsayso campaign to raise awareness about hypertension. Are you ready to help us 🗣️ spread the word and share our Facebook and Instagram campaigns? Together, let’s 🗣️ spread the word and encourage everyone to take control of their health. 👉 Learn more: https://bit.ly/3E7s4Lj #TakeControl #HypertensionAwareness #AsOne
-
Servier Ventures, our newly created corporate venture fund, is proud to announce its first investment, supporting Cytospire Therapeutics Ltd in its Series A financing.
We’re excited to share that Cytospire has completed an oversubscribed £61m ($83m) Series A financing, led by 4BIO Capital with major investors Servier Ventures, Abingworth, British Business Bank, Sound Bioventures, Criteria Bio Ventures and LifeArc Ventures. This is a huge milestone for the company and a strong vote of confidence in Cytospire’s vision to build a new generation of cancer immunotherapies. The funding enables us to advance our lead programme, CYT X300, into the clinic and continue to build out our growing portfolio of differentiated multispecific engager antibodies. At Cytospire, we’re developing therapies designed to precisely engage both tissue/ tumour‑resident and blood resident gamma delta T cells — with the goal of unlocking safer and more effective treatments against well‑validated cancer targets that have remained out of reach for conventional CD3‑based engager approaches. In addition to our major investors, we are also delighted to welcome Modi Ventures, Medical Incubator Japan and Pathway Bioventures to our syndicate. A huge thank you to our investors, partners and, most importantly, the fantastic Cytospire team. We’re just getting started — and we’re excited about what’s ahead as we move toward the clinic. 🔗 Read more about the financing: https://bit.ly/4w9wV8r #Cytospire #SeriesA #Biotech #CancerImmunotherapy #ImmunoOncology #LifeSciences 🚀
-